Showing results (1-10 of 122) with videos related to
Sort By:
Pageof 13
Theoretical Biology & Medical Modelling|August 7, 2014
Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancersMatthew A Firpo, Kenneth M Boucher, Sean J MulvihillBMC Bioinformatics|December 9, 2008
Empirical methods for controlling false positives and estimating confidence in ChIP-Seq peaksDavid A Nix, Samir J Courdy, Kenneth M BoucherPlos One|December 7, 2017
The association between socioeconomic factors and breast cancer-specific survival varies by raceShailesh Agarwal, Jian Ying, Kenneth M Boucher, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|July 28, 2011
A decade of melanomas: identification of factors associated with delayed detection in an academic group practiceAgnessa Gadeliya Goodson, Scott R Florell, Kenneth M Boucher, et al.Journal of the American Academy of Dermatology|December 19, 2009
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic neviAgnessa Gadeliya Goodson, Scott R Florell, Kenneth M Boucher, et al.Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|August 27, 2013
Effect of brachytherapy technique and patient characteristics on cervical cancer implant dosimetryChristopher J Anker, Kristen O'Donnell, Kenneth M Boucher, et al.The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 20, 2007
Longevity and correlated frailty in multigenerational familiesGilda Garibotti, Ken R Smith, Richard A Kerber, et al.Cancer Epidemiology|October 3, 2015
Conditional survival for pediatric and adolescent patients with cancer: Implications for survivorship careSapna Kaul, Anne C Kirchhoff, Kenneth M Boucher, et al.Human Mutation|July 29, 2020
Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelinesSean V Tavtigian, Steven M Harrison, Kenneth M Boucher, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2009
A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancerWallace Akerley, Kenneth M Boucher, Joel S Bentz, et al.Pageof 13